WEBINAR: Normalization of organ-on-a-chip samples for mass spectrometry based proteomics and metabolomics via dansylation-based assay – 28 June 2023

cnb825 webinar promo v1 |
Learn more
cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo
  • Products
    • Explore our solutions


      PhysioMimix® products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Liver-on-a-chip model
      • Multi-organ models

      Support packages

      • PhysioMimix® support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix® products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • Oncology
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

      Oncology icon

      Oncology

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • Immune-mediated DILI – Predicting the unpredictable!

      • CN Bio appoints Deepak Singh as Vice President of Sales and Marketing

      • CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System  

      View all news

      Upcoming Events

      • ISSX DMDG 2023

      • MPS World Summit Berlin 2023

      View all events

      Join the team!

      View all jobs
  • Contact
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to footer
Chat live with an expert

Fully human in vitro gut-liver model of non-alcoholic steatohepatitis

June 11, 2017 by

Resource > Posters >

Fully human in vitro gut-liver model of non-alcoholic steatohepatitis


American Association for the Study of Liver Diseases (AASLD)

Filed under: Disease modeling and NAFLD/NASH

Fully human in vitro gut liver model of NASH EDIT |

Kostrzewski et al 

Non-Alcoholic Fatty Liver Disease(NAFLD) represents a wide spectrum of liver abnormalities with the most severe cases involving progressive liver injury in the form Non-Alcoholic Steatohepatitis (NASH). Key characteristics of NASH include lipid accumulation in hepatocytes, chronic inflammation and extracellular matrix deposition, leading to fibrosis. NASH is the liver manifestation of the metabolic syndrome, with close association with insulin resistance, obesity and Type 2 diabetes. The interaction between the liver and the gut (the “gut-liver axis”), is now known to play a critical role in NAFLD onset and progression. Dietary factors and gut microbiota can both alter intestinal barrier function, leading to metabolic endotoxemia and low-grade inflammation which will contribute to the development of NAFLD.​

There is a requirement for better preclinical models to understand the molecular mechanisms underlying NAFLD/NASH. Particularly models that mimic disease progression in the liver with linked interactions to the gut, adipose tissue and immune system will have the highest translational relevance. This is particularly prevalent as there remains no FDA approved drugs for the treatment of NAFLD/NASH.​

Using perfused microphysiological cell culture systems, we aimed to develop a fully human in vitro NAFLD/NASH model, utilizing primary human hepatocytes (PHH), Kupffer (HK) and hepatic stellate cells (HSC). The complexity of this model was further enhanced by combining the NASH liver model with an in vitro gut model to allow the interactions of the two organs to be studied.​

Utilizing perfused MPS culture platforms, we have generated fully human models of NASH liver and NASH gut/liver. Combining the gut and NASH liver models, we demonstrate gut-liver crosstalk where by inflammation from the NASH liver was increased when LPS leaked from gut epithelium. These in vitro NASH models are ideally suited to exploring the molecular mechanisms that underlie the development of human NASH and will be a useful tool for analyzing the efficacy of novel anti-NASH therapeutics against a range of different target pathways.

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Terms | Regulatory | Accessibility | Recycling

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • Immune-mediated DILI – Predicting the unpredictable! March 16, 2023
  • CN Bio appoints Deepak Singh as Vice President of Sales and Marketing March 14, 2023
  • CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System   February 27, 2023

Upcoming events

ISSX DMDG 2023 June 11-14, 2023

MPS World Summit Berlin 2023 June 26-30, 2023